BofA analyst Tazeen Ahmad raised the firm’s price target on Apellis to $84 from $77 and keeps a Buy rating on the shares after the company reported Q4 results and highlighted the strong performance of the Syfovre launch despite headwinds in 2023. Management commented that despite seeing some seasonality in Q1, January and February were the two of strongest months since the launch and they continue to see strong demand heading into March, notes the analyst, who remains encouraged by the strong commercial performance of Syfovre in the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- Apellis expects cash to fund expenditures for ‘foreseeable future’
- Apellis reports Q4 EPS (73c), consensus (69c)
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- APLS Earnings this Week: How Will it Perform?